Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $44 from $37 and keeps a Buy rating on the shares. The firm said they reported Q3 results and noted Ohtuvayre initial sales beat expectations.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
- Verona Pharma Faces Financial Risks Amid Medicaid Rebate Program Compliance Challenges
- Verona Pharma Reports Strong Q3 Launch for COPD Drug
- Verona Pharma reports Q3 EPS (7c), consensus (50c)
- Verona Pharma price target raised to $64 from $50 at Wells Fargo